Cover storyPharma’s Next Operating Model: Governed Intelligence, Not Automation for Its Own Sake
Explore how pharma leaders can build governed AI systems that improve manufacturing without compromising quality or accountability.
Cover storyExplore how pharma leaders can build governed AI systems that improve manufacturing without compromising quality or accountability.

EMA's CHMP issued six positive opinions in October 2026, including oral GLP-1 orforglipron and two biosimilars, with key implications for EU market entry.
Adial Pharmaceuticals names tapinarof architect David Rubenstein as Chief Scientist to lead AT177 through IND-enabling studies toward 2027 first-in-human trials.

Dermata Therapeutics reports topline cosmetic study data for Tome Foundational Treatment, with 71% of participants showing improvement after one application.

Oryzon secures vafidemstat patent grants in South Korea, Philippines, New Zealand, and Mexico ahead of a Phase III BPD trial.
Latest edition
SPONSORED
SPONSORED
SPONSORED
Oct 20
Oct 28From native content to event partnerships, we help brands earn the attention of a hard-to-reach, senior audience — without breaking the reading experience.
See partnership options →Explore expert-led guides crafted for pharma professionals. Log in to download and stay ahead.








Join thousands of pharma professionals getting our sharpest reporting, briefings and guides — free.
